Johnson & Johnson (NYSE:JNJ) saw strong trading volume on Tuesday . 6,130,723 shares were traded during mid-day trading, an increase of 3% from the previous session’s volume of 5,966,640 shares.The stock last traded at $120.76 and had previously closed at $122.31.

A number of equities research analysts have weighed in on the company. Leerink Swann reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Sunday, May 22nd. BTIG Research reiterated a “hold” rating on shares of Johnson & Johnson in a research note on Sunday, May 22nd. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price objective for the company in a research note on Friday, August 5th. Deutsche Bank AG reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Thursday, May 19th. Finally, Barclays PLC reiterated an “overweight” rating and issued a $120.00 price objective (up previously from $115.00) on shares of Johnson & Johnson in a research note on Wednesday, April 20th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $119.30.

The firm has a 50-day moving average of $123.31 and a 200-day moving average of $113.51. The firm has a market cap of $329.21 billion and a PE ratio of 22.42.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.68 by $0.06. The firm earned $18.50 billion during the quarter, compared to analysts’ expectations of $17.98 billion. Analysts predict that Johnson & Johnson will post $6.69 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 19th. Shareholders of record on Friday, August 5th will be given a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 0.96%.

In other news, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $125.01, for a total transaction of $366,904.35. Following the sale, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Gary J. Pruden sold 9,735 shares of Johnson & Johnson stock in a transaction dated Tuesday, June 7th. The shares were sold at an average price of $116.03, for a total transaction of $1,129,552.05. Following the sale, the vice president now directly owns 43,630 shares in the company, valued at approximately $5,062,388.90. The disclosure for this sale can be found here.

Several large investors recently made changes to their positions in the stock. Reik & CO. LLC raised its stake in shares of Johnson & Johnson by 0.3% in the fourth quarter. Reik & CO. LLC now owns 15,942 shares of the company’s stock worth $1,637,000 after buying an additional 40 shares during the last quarter. Ancora Advisors LLC raised its stake in shares of Johnson & Johnson by 0.3% in the fourth quarter. Ancora Advisors LLC now owns 60,631 shares of the company’s stock worth $6,340,000 after buying an additional 165 shares during the last quarter. First Merchants Corp raised its stake in shares of Johnson & Johnson by 0.5% in the fourth quarter. First Merchants Corp now owns 36,541 shares of the company’s stock worth $3,754,000 after buying an additional 170 shares during the last quarter. CG Asset Management LLC raised its stake in shares of Johnson & Johnson by 0.3% in the fourth quarter. CG Asset Management LLC now owns 55,737 shares of the company’s stock worth $5,725,000 after buying an additional 181 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its stake in shares of Johnson & Johnson by 1.2% in the fourth quarter. Parkside Financial Bank & Trust now owns 19,710 shares of the company’s stock worth $2,025,000 after buying an additional 231 shares during the last quarter.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.